Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

Completed · Phase 2

Conditions studied: Non-small Cell Lung Cancer Stage IV

In brief

This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of anti-cancer therapy. A maximum of 60 evaluable patients with NSCLC will receive antroquinonol, of which 30 patients will be KRAS-positive and 30 patients KRAS-negative. An evaluable patient will have received at least one dose of antroquinonol and have a valid baseline tumor assessment. Enrollment will continue until the target number of evaluable patients has been enrolled.

Key facts

Study ID

NCT02047344

Run by

Golden Biotechnology Corporation

People needed

31

Starts

2013-10-01

Expected to finish

2018-12-07

Last updated by the study team

2019-12-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion).
• Radiologically confirmed disease progression following two previous lines of anti-cancer therapy, one of which should be a platinum based regimen, OR the patient has refused treatment with approved treatment modalities
• At least one radiologically measurable target lesion per RECIST version 1.1
• Fresh or archival biopsy tissue available to determine tumor mutation status
• Written informed consent that is consistent with International Conference on Harmonisation Tripartite Guideline on Good Clinical Practice guidelines
• Patient or legally acceptable representative has granted written informed consent before any study specific procedures (including special Screening tests) are performed
• Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2
• Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L; absolute neutrophil count ≥ 1.5 x 109/L without the use of hematopoietic growth factors
• Bilirubin and creatinine less than 2 × upper limit of normal (ULN) for the institution
• Albumin ≥ 2.5 mg/dL
• Aspartate aminotransferase and alanine aminotransferase less than 5 × ULN for the institution
• Prothrombin time less than 1.5 × ULN for the institution
• Potassium, magnesium and phosphorus within the normal range for the institution (supplementation is permissible)
• Recovery to Grade 1 or baseline of any toxicities due to prior treatments, excluding alopecia

You may not qualify if…

• Chemo-, hormone- or immunotherapy, within 4 weeks or within less than four half lives of the date of first administration of study drug and/or persistence of toxicities of prior anti-cancer therapies which are deemed to be clinically relevant
• Radiotherapy within the past 2 weeks prior to date of first administration of study drug
• Previous treatment with an histone deacetylase inhibitor or an epidermal growth factor receptor inhibitor within at least 4 weeks of the date of first administration of study drug
• Treatment with any drug(s) known to be an inhibitor or inducer of cytochrome P450 (CYP)2C19, CYP3A4, CYP2C8, and CYP2E1, within 14 days of the date of first administration of study drug
• Brain metastases, which are symptomatic; patients with treated, brain metastases are eligible with stable brain disease for at least 4 weeks without the requirement for steroids or anti epileptic therapy
• Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Cohn's disease, malabsorption, or Common Terminology Criteria for Adverse Event (CTCAE) Grade > 2 diarrhea of any etiology at baseline
• Other malignancies diagnosed within the past five years (other than curatively treated cervical cancer in situ), non melanoma skin cancer, superficial bladder tumors Ta (non invasive tumor) and TIS (carcinoma in situ)
• Patients with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent)
• Patients with known human immunodeficiency virus, active hepatitis B or active hepatitis C
• Patients who have any other life threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the study drug
• Known or suspected substance abuse or alcohol abuse
• Pregnancy or breast feeding
• History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association functional classification of three

Where it is running

• Arizona Clinical Research Center — Tucson, Arizona, United States
• UCSF — San Francisco, California, United States
• Rush University Medical Center — Chicago, Illinois, United States
• John Hopkins University — Baltimore, Maryland, United States
• Peninsula Regional Med Center — Salisbury, Maryland, United States
• Henry Ford health system — Detroit, Michigan, United States
• Guthrie Clinic, Ltd — Sayre, Pennsylvania, United States
• Chang Gung Memorial Hospital-Kaohsiung medical center — Kaohsiung City, Taiwan
• National Cheng Kung University Hospitail — Tainan, Taiwan
• Tri Service General Hospital — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.